BiondVax Pharmaceuticals

162 articles with BiondVax Pharmaceuticals

• BiondVax Announces Upcoming Expiration of Public Warrants

  5/4/2020

  BiondVax Pharmaceuticals Ltd., developer of the universal influenza vaccine candidate M-001, published a reminder that its publicly traded warrants will expire, according to their terms, on May 15, 2020.

• New Directors Elected to BiondVax's Board of Directors

  3/24/2020

  BiondVax Pharmaceuticals Ltd., developer of the universal influenza vaccine candidate M-001, announced that all proposed resolutions were approved at the Company's Annual General Meeting held, including the election of three new directors to the Company's Board of Directors, namely, Dr. Yael Margolin, Mr. Adi Raviv, and Mr. Samuel Moed.

• BiondVax's CEO Comments on Impact of COVID-19 Pandemic on the Company's Ongoing Phase 3 Clinical Trial

  3/19/2020

  BiondVax Pharmaceuticals Ltd. issued an update regarding the impact of the COVID-19 pandemic on the ongoing pivotal, clinical efficacy, Phase 3 trial in Europe of the Company's M-001 universal influenza vaccine candidate..

• BiondVax Announces Warrant Agreement Amendment to Permit Holders of Warrants to Exercise Both on a Cash and Cashless Basis

  1/16/2020

  Warrant holders will continue to be able to exercise their Warrants on a cash basis as well. 

• Enrollment and Randomization of 12,463 Participants Complete in BiondVax's Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine trial

  11/18/2019

  BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced today that enrollment and randomization of 12,463 participants in the pivotal, clinical efficacy, Phase 3 trial of the M-001 universal influenza vaccine candidate is complete.

• BiondVax Receives €4M From the European Investment Bank (EIB) in Support of Ongoing Universal Influenza Vaccine Pivotal Phase 3 Trial

  10/7/2019

  BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a phase 3 clinical stage biopharmaceutical company focused on developing and commercializing the M-001 clinical Phase 3 Universal Influenza Vaccine candidate, announced today the receipt of €4 million from the European Investment Bank (EIB).

• BiondVax Welcomes New Chairman of the Board and Announces Second Quarter 2019 Financial Results

  8/28/2019

  Professor Avner Rotman, who has served as BiondVax's Chairman since 2005, will continue to serve as a Director.

• BiondVax Announces Rights Offering Fully Subscribed at US$20 Million

  7/16/2019

  Funds to complete ongoing pivotal, clinical efficacy, Phase 3 trial of the M-001 Universal Flu Vaccine candidate and scale-up manufacturing

• First Participant Enrolled in Second Cohort of BiondVax's Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine Trial

  7/8/2019

  BiondVax Pharmaceuticals Ltd. announced that the first participants in the second cohort of the pivotal, clinical efficacy, Phase 3 trial of the M-001 universal flu vaccine candidate have been successfully enrolled.

• Patent Covering Manufacturing Process of BiondVax's M-001 Universal Flu Vaccine Allowed in USA and Japan

  6/18/2019

  Pivotal Clinical Efficacy Phase 3 Clinical Trial Results Expected in 2020

• BiondVax Announces Rights Offering in Support of Ongoing Pivotal, Clinical Efficacy Phase 3 Trial of the M-001 Universal Flu Vaccine and Scale Up of Manufacturing Process

  6/10/2019

  The Company anticipates results of the Phase 3 trial will be announced by the end of 2020.

• BiondVax Announces First Quarter 2019 Financial Results

  5/30/2019

  BiondVax Pharmaceuticals Ltd. announced its financial results for the quarter ended March 31, 2019.

• BiondVax to Provide Update of M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial at 18th MIXiii-BIOMED Conference

  5/13/2019

  BiondVax Pharmaceuticals Ltd., developer of the M-001 universal influenza vaccine candidate, reported it will present this week at the 18th MIXiii-BIOMED Conference and Exhibition in Tel Aviv, Israel.

• BiondVax Announces Fourth Quarter and Full Year 2018 Financial Results and Update

  4/30/2019

  BiondVax Pharmaceuticals Ltd. announced its fourth quarter and full year financial results for the year ended December 31, 2018 and provided a business update.

• European Investment Bank (EIB) Extends Financing Agreement to €24 Million Total in Support of BiondVax's Universal Flu Vaccine Ongoing Pivotal Phase 3 Clinical Trial

  4/22/2019

  €4 million extension to 2017 financing agreement

• BiondVax Universal Flu Vaccine Patent Application Accepted in Australia

  4/15/2019

  The patent application has been filed in eight other jurisdictions, and is under examination in Europe, China, Japan, and the USA.

• BiondVax to Provide Update of M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial at IVW2019 Conference

  3/28/2019

  BiondVax Pharmaceuticals Ltd. reported it will present next week at the Influenza Vaccines for the World conference in Edinburgh, Scotland, UK.

• Last Participant out in USA Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate

  3/21/2019

  BiondVax Pharmaceuticals Ltd. reported that all participants have completed their final visit in a Phase 2 clinical trial conducted by several Vaccine Treatment and Evaluation Units sponsored by the National Institute of Allergy and Infectious Diseases, part of the U.S. Department of Health & Human Services's National Institutes of Health.

• BiondVax CEO to Present at 'World Vaccine Congress 2018 San Diego' About BiondVax's Phase 3 Universal Flu Vaccine Candidate

  11/26/2018

  BiondVax Pharmaceuticals Ltd. reported today it will present this week at the World Vaccine & Immunotherapy Congress West Coast 2018 in San Diego.

• BiondVax Issues Clarification Regarding Third Quarter 2018 Financial Results

  11/19/2018

  BiondVax is a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate.